© The Institution of Engineering and Technology
At early drug discovery, purified protein-based assays are often used to characterise compound potency. In the context of dose response, it is often perceived that a time-independent inhibitor is reversible and a time-dependent inhibitor is irreversible. The legitimacy of this argument is investigated using a simple kinetics model, where it is revealed by model-based analytical analysis and numerical studies that dose response of an irreversible inhibitor may appear time-independent under certain parametric conditions. Hence, the observation of time-independence cannot be used as sole evidence for identification of inhibitor reversibility. It has also been discussed how the synthesis and degradation of a target receptor affect drug inhibition in an in vitro cell-based assay setting. These processes may also influence dose response of an irreversible inhibitor in such a way that it appears time-independent under certain conditions. Furthermore, model-based steady-state analysis reveals the complexity nature of the drug–receptor process.
References
-
-
1)
-
17. Nagar, S., Jones, J.P., Korzekwa, K.: ‘A numerical method for analysis of in vitro time-dependent inhibition aata. Part 1. theoretical considerations’, Drug Metab. Dispos., 2014, 42, (9), pp. 1575–1586 (doi: 10.1124/dmd.114.058289).
-
2)
-
8. Gibiansky, L., Gibiansky, E.: ‘Target-mediated drug disposition model: relationships with indirect response models and application to population PK–PD analysis’, J. Pharmacokinet. Pharmacodyn., 2009, 36, (4), pp. 341–351 (doi: 10.1007/s10928-009-9125-9).
-
3)
-
19. You, T., Stansfield, I., Romano, M.C., Brown, A.J., Coghill, G.M.: ‘Analysing GCN4 translational control in yeast by stochastic chemical kinetics modelling and simulation’, BMC Syst. Biol., 2011, 5, (1), p. 131 (doi: 10.1186/1752-0509-5-131).
-
4)
-
21. Hendriks, B.S., Opresko, L.K., Wiley, H.S., Lauffenburger, D.: ‘Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations quantitative analysis of HER2 overexpression effects’, Cancer Res., 2003, 63, (5), pp. 1130–1137.
-
5)
-
12. Aston, P.J., Derks, G., Agoram, B.M., Van Der Graaf, P.H.: ‘A mathematical analysis of rebound in a target-mediated drug disposition model: I. Without feedback’, J. Math. Biol., 2014, 68, (6), pp. 1453–1478 (doi: 10.1007/s00285-013-0675-5).
-
6)
-
20. Lauffenburger, D.A., Linderman, J.J.: ‘Receptors: models for binding, trafficking, and signaling’ (Oxford University Press, New York, 1993).
-
7)
-
4. Marathe, A., Krzyzanski, W., Mager, D.E.: ‘Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model’, J. Pharmacokinet. Pharmacodyn., 2009, 36, (3), pp. 199–219 (doi: 10.1007/s10928-009-9118-8).
-
8)
-
18. Copeland, R.A., Pompliano, D.L., Meek, T.D.: ‘Drug–target residence time and its implications for lead optimization’, Nat. Rev. Drug Discov., 2006, 5, (9), pp. 730–739 (doi: 10.1038/nrd2082).
-
9)
-
5. Yan, X., Mager, D.E., Krzyzanski, W.: ‘Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models’, J. Pharmacokinet. Pharmacodyn., 2010, 37, (1), pp. 25–47 (doi: 10.1007/s10928-009-9142-8).
-
10)
-
1. Sorger, P.K., Allerheiligen, S.R., Abernethy, D.R., et al: ‘Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms’. An NIH White Paper by the QSP Workshop Group, NIH, Bethesda, 2011, pp. 1–48.
-
11)
-
9. Orrell, D., Fernandez, E.: ‘Using predictive mathematical models to optimise the scheduling of anti-cancer drugs’, Innov. Pharm. Technol., 2010, 33, pp. 58–62.
-
12)
-
2. Gibiansky, L., Gibiansky, E.: ‘Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic and pharmacodynamic modeling of biologics’, Expert Opin. Drug Metab. Toxicol., 2009, 5, (7), pp. 803–812 (doi: 10.1517/17425250902992901).
-
13)
-
15. Aston, P.J., Derks, G., Raji, A., Agoram, B.M., Van Der Graaf, P.H.: ‘Mathematical analysis of the pharmacokinetic–pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency’, J. Theor. Biol., 2011, 281, (1), pp. 113–121 (doi: 10.1016/j.jtbi.2011.04.030).
-
14)
-
10. Yankeelov, T.E., Atuegwu, N., Hormuth, D., et al: ‘Clinically relevant modeling of tumor growth and treatment response’, Sci. Transl. Med., 2013, 5, (187), pp. 187ps9–187ps9 (doi: 10.1126/scitranslmed.3005686).
-
15)
-
7. Mager, D.E., Krzyzanski, W.: ‘Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition’, Pharm. Res., 2005, 22, (10), pp. 1589–1596 (doi: 10.1007/s11095-005-6650-0).
-
16)
-
11. Bonate, P.: ‘What happened to the modeling and simulation revolution?’, Clin. Pharmacol. Ther., 2014, 96, (4), pp. 416–417 (doi: 10.1038/clpt.2014.123).
-
17)
-
6. Vicini, P.: ‘Multiscale modeling in drug discovery and development: future opportunities and present challenges’, Clin. Pharmacol. Ther., 2010, 88, (1), pp. 126–129 (doi: 10.1038/clpt.2010.87).
-
18)
-
22. Schwartz, P.A., Kuzmic, P., Solowiej, J., et al: ‘Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance’, Proc. Nat. Acad. Sci., 2014, 111, (1), pp. 173–178 (doi: 10.1073/pnas.1313733111).
-
19)
-
16. Strelow, J., Dewe, W., Iversen, P., et al: , 2004.
-
20)
-
13. Peletier, L.A., Gabrielsson, J.: ‘Dynamics of target-mediated drug disposition’, Eur. J. Pharm. Sci., 2009, 38, (5), pp. 445–464 (doi: 10.1016/j.ejps.2009.09.007).
-
21)
-
3. Ma, P.: ‘Theoretical considerations of target-mediated drug disposition models: simplifications and approximations’, Pharm. Res., 2012, 29, (3), pp. 866–882 (doi: 10.1007/s11095-011-0615-2).
-
22)
-
14. Peletier, L.A., Gabrielsson, J.: ‘Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification’, J. Pharmacokinet. Pharmacodyn., 2012, 39, (5), pp. 429–451 (doi: 10.1007/s10928-012-9260-6).
http://iet.metastore.ingenta.com/content/journals/10.1049/iet-syb.2015.0037
Related content
content/journals/10.1049/iet-syb.2015.0037
pub_keyword,iet_inspecKeyword,pub_concept
6
6